Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | APAF1 | O14727 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7679244 | 0.83 | CHEK1 (0.53) | KDRPDGFRBFGFR1CHEK1 | |
| SCHEMBL7699614 | 0.82 | KDR (0.56) | KDRPDGFRBFGFR1CHEK1 | |
| SCHEMBL7681394 | 0.71 | KDR (0.49) | KDRPDGFRBFGFR1CHEK1 | |
| SCHEMBL6157677 | 0.70 | KDR (0.69) | KDRPDGFRBFGFR1ALDH1A1KDM4E | |
| SCHEMBL7673824 | 0.69 | KDR (0.47) | KDRPDGFRBFGFR1CHEK1 | |
| SCHEMBL5138068 | 0.69 | CHEK1 (0.74) | KDRCHEK1 | |
| SCHEMBL6159805 | 0.69 | KDR (0.65) | KDRPDGFRBFGFR1HPGD | |
| SCHEMBL7682337 | 0.69 | KDR (0.54) | KDRPDGFRBFGFR1 | |
| SCHEMBL6159113 | 0.69 | KDR (0.74) | KDRPDGFRBFGFR1ALDH1A1KDM4E | |
| SCHEMBL7677131 | 0.68 | KDR (0.53) | KDRPDGFRBFGFR1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6479512-B1 | TO TREAT TYROSINE KINASE-DEPENDENT DISEASES AND CONDITIONS, SUCH AS ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES, ETC. | MERCK & CO., INC. | 2002-11-12 | — | — | US | disclosed |